Unity Biotechnology Inc (UBX) Shares Bought by Capital World Investors
Capital World Investors lifted its stake in Unity Biotechnology Inc (NASDAQ:UBX) by 371.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,035,000 shares of the company’s stock after purchasing an additional 815,511 shares during the period. Capital World Investors owned about 2.45% of Unity Biotechnology worth $16,860,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Redmile Group LLC bought a new position in shares of Unity Biotechnology in the second quarter worth about $3,771,000. Laurion Capital Management LP bought a new position in shares of Unity Biotechnology in the second quarter worth about $1,927,000. Citadel Advisors LLC bought a new position in shares of Unity Biotechnology in the second quarter worth about $230,000. Schwab Charles Investment Management Inc. bought a new position in shares of Unity Biotechnology in the second quarter worth about $309,000. Finally, Partner Investment Management L.P. bought a new position in shares of Unity Biotechnology in the second quarter worth about $4,079,000. Hedge funds and other institutional investors own 30.12% of the company’s stock.
Shares of Unity Biotechnology stock opened at $15.11 on Tuesday. Unity Biotechnology Inc has a 52 week low of $10.33 and a 52 week high of $24.56.
Several research analysts have issued reports on UBX shares. Zacks Investment Research cut shares of Unity Biotechnology from a “buy” rating to a “hold” rating in a report on Friday, October 12th. Mizuho started coverage on shares of Unity Biotechnology in a report on Thursday, September 6th. They set a “buy” rating and a $33.00 target price on the stock. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Unity Biotechnology has a consensus rating of “Buy” and a consensus price target of $25.00.
Unity Biotechnology Profile
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
Read More: Retained Earnings
Want to see what other hedge funds are holding UBX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Unity Biotechnology Inc (NASDAQ:UBX).
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.